M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2014, Pages 1883-1890

  Hoxha, Elion ^a   Harendza, Sigrid ^a   Pinnschmidt, Hans ^a   Panzer, Ulf ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; PHOSPHOLIPASE A2 RECEPTOR AUTOANTIBODY; RITUXIMAB; SERUM ALBUMIN; UNCLASSIFIED DRUG; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PHOSPHOLIPASE A2 RECEPTOR; PROTEIN;

ADULT; AGE; ARTICLE; CLINICAL DECISION MAKING; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTICENTER STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; RISK FACTOR; AGED; BLOOD; CLINICAL TRIAL; DISEASE COURSE; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SEX DIFFERENCE; URINE;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINS; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; RITUXIMAB; SEX FACTORS;

EID: 84923930941     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03850414     Document Type: Article

References (21)

1. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85–89, 1993
2. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444–450, 1998
3. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899–1904, 2007
4. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasá M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416–1425, 2012
5. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484–490, 2001
6. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901–907, 1997
7. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009
8. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25: 1357–1366, 2014
9. Beck LH Jr., Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543–1550, 2011
10. Hofstra JM, Beck LH Jr., Beck DM, Wetzels JF, Salant DJ: Antiphospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286–1291, 2011
11. Hofstra JM, Debiec H, Short CD, Pelle´ T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1735–1743, 2012
12. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83: 940–948, 2013
13. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA: An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26: 2526–2532, 2011
14. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W: Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421: 213–218, 2013
15. Ehrenreich T, Churg J: Pathology of membranous nephropathy. Pathol Annu 3: 145–186, 1968
16. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, Troyanov S; Genes, Gender and Glomerulonephritis Group: The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23: 2247–2253, 2008
17. Bohle A, Wehrmann M, Bogenschütz O, Batz C, Vogl W, Schmitt H, Müller CA, Müller GA: The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 188: 908–924, 1992
18. Sprangers B, Bomback AS, Cohen SD, Radhakrishnan J, Valeri A, Markowitz GS, D’Agati V, Appel GB: Idiopathic membranous nephropathy: Clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center. Am J Nephrol 36: 78–89, 2012
19. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, Gaskin GJ, Jayne DR, O’Donoghue D, Boulton-Jones M, Mathieson PW: Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial. Lancet 381: 744–751, 2013
20. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481–508, 2009
21. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324–332, 2003